CYP2C9 ACTIVITY IN TURKISH PATIENTS WITH RHEUMATOID ARTHRITIS

被引：0
|
作者：
Ozer, E. K. [1 ]
Albayrak, I. [2 ]
Goktas, M. T. [3 ]
机构：
[1] Selcuk Univ, Fac Med, Dept Pharmacol, Konya, Turkey
[2] Selcuk Univ, Fac Med, Dept Phys Med & Rehabil, Konya, Turkey
[3] Yildirim Beyazit Univ, Fac Med, Dept Pharmacol, Ankara, Turkey
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
关键词：
D O I：
10.1136/annrheumdis-2016-eular.2259
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0200
引用
收藏
页码：965 / 966
页数：2
相关论文
共 50 条
  • [21] The Relationship Between Warfarin Resistance and CYP2C9*2 and CYP2C9*3 Variations
    Kirac, Deniz
    Yaman, Aysun Erdem
    Doran, Tansu
    Altunok, Elif Cigdem
    MEDICAL JOURNAL OF BAKIRKOY, 2021, 17 (03) : 209 - 213
  • [22] CYP2C9 polymorphism in patients on phenytoin therapy
    Sevinç, D
    Özkaynakçi, AE
    Özkara, Ç
    Uzan, M
    Koçer, A
    Aker, R
    Özyurt, HB
    Güney, AI
    Onat, F
    EPILEPSIA, 2005, 46 : 259 - 259
  • [23] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Shaul, Chanan
    Blotnick, Simcha
    Adar, Liat
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1187 - 1198
  • [24] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Chanan Shaul
    Simcha Blotnick
    Liat Adar
    Mordechai Muszkat
    Meir Bialer
    Yoseph Caraco
    Clinical Pharmacokinetics, 2022, 61 : 1187 - 1198
  • [25] Effect of cigarette smoking on CYP2C9 activity.
    Kim, M
    LaCourse, J
    Nafziger, AN
    Wallace, AL
    Kashuba, AD
    Rowland, E
    Gaedigk, A
    Bertino, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P14 - P14
  • [26] Post-PCR detection and discrimination of the CYP2C9*1, CYP2C9*2, and CYP2C9*3 SNPs using gene probes.
    Goldford, M
    Backus, J
    Triscott, M
    CLINICAL CHEMISTRY, 2000, 46 (11) : 1878 - 1878
  • [27] Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9☆59
    Dai, Da-Peng
    Wang, Shuang-Hu
    Li, Chuan-Bao
    Geng, Pei-Wu
    Cai, Jie
    Wang, Hao
    Hu, Guo-Xin
    Cai, Jian-Ping
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1246 - 1249
  • [28] Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis
    Ercan, B.
    Ayaz, L.
    Cicek, D.
    Tamer, L.
    CELL BIOCHEMISTRY AND FUNCTION, 2008, 26 (03) : 309 - 313
  • [29] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    G. Oner Ozgon
    T. Y. Langaee
    H. Feng
    N. Buyru
    T. Ulutin
    A. C. Hatemi
    A. Siva
    S. Saip
    J. A. Johnson
    European Journal of Clinical Pharmacology, 2008, 64 : 889 - 894
  • [30] VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients
    Ozgon, G. Oner
    Langaee, T. Y.
    Feng, H.
    Buyru, N.
    Ulutin, T.
    Hatemi, A. C.
    Siva, A.
    Saip, S.
    Johnson, J. A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (09) : 889 - 894
12345